Eli Lilly will hardly be the first in the field of GLP-1 treatments for diabetes if and when it launches dulaglutide, but the company believes its drug has the data to stand out among its rivals and claim the lion's share of a multibillion-dollar market.
Lilly has hit another setback in its effort to expand the market range for its key cancer drug ramucirumab, recently approved as Cyramza for stomach cancer.
The abstracts for the upcoming scientific conference of the ADA hit Friday, and top analyst Mark Schoenebaum at ISI flagged a critical issue for Eli Lilly's top drug candidate dulaglutide that could come back to haunt the troubled pharma giant after it reaches the market with its GLP-1 contender.
What's the best defense against all those fake versions of Viagra and other prescription erectile dysfunction pills that are sold online directly to men looking for a boost in the bedroom? Sanofi believes it has the answer: an over-the-counter version of Eli Lilly's ED blockbuster Cialis.
A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.
Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning letter for the facility.
Boehringer Ingelheim's manufacturing facility in Ingelheim, Germany has generated a lot of mail from the FDA. Finally, some good news: The company said today it received a letter from the FDA clearing the plant, meaning it and partner Eli Lilly can move forward with empagliflozin.
In keeping with changing industry standards, Eli Lilly has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all.
Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug.
Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.